NL-OMON38390已完成2 期
Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A phase II, Multi-center, double-blind, ascending dose, placebo-controlled, dose-finding trial of CER-001 or placebo in subjects with acute coronary syndrome. - CHI SQUARE
Cerenis Therapeutics SA0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •male or female up to and including 80 years of age, acute chest pain and diagnosis of ST segment elevation or non-ST elevation myocadial infarction or unstable angina, clincally indicated coranary angiography, evidence of coronary artery disease, and an appropriate target coronary artery.
排除标准
- •Subjects weighing more than 160 kg, uncontrolled diabetes, triglycerides greater than 500 mg/dl, baseline ivus of unacceptable quality, subjects for whom CABG is planned, hemodynamically or clinically unstable, and ejcection fraction less than 35%.
研究者
相似试验
尚未招募
不适用
High HDL cholesterol and ASCVD risk scoreCTRI/2019/12/022320Kasturba Medical College
已完成
3 期
High-Density Lipoprotein (HDL) Modulation and Endothelial FunctionAtherosclerosisNCT00150722University of Calgary75
已完成
不适用
Anti-atherosclerosis effects of 12 weeks high intensity interval and aerobic training on serum levels salusin-a and -ß, nitric oxide, inflammatory markers and lipid profile in overweight and obese childrensAnti-Atherosclerosis Effects of exercise.IRCT20200116046154N1Razi University45
进行中（未招募）
4 期
Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD TrialCardiovascular DiseaseNCT05361421Yonsei University1,200
已完成
不适用
Improving Metabolism With HDL CholesterolHeart DiseaseDiabetesNCT00395148Bayside Health13